From: Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision
 | Disease free survival | Overall survival | |||
---|---|---|---|---|---|
HR | (p) | HR | (p) | ||
Clinical-pathological features | Age | 1.93 | (0.2) | 1.71 | (0.3) |
Sex | 0.70 | (0.5) | 0.81 | (0.7) | |
Tumour location | 1.50 | (0.4) | 1.85 | (0.2) | |
Tumour grade | 1.29 | (0.7) | 0.81 | (0.7) | |
5-FU treatment | 1.23 | (0.7) | 1.12 | (0.8) | |
Depth of tumour invasion | 0.94 | (0.9) | 1.27 | (0.7) | |
Lymphovascular invasion | 0.70 | (0.4) | 0.61 | (0.3) | |
Large veins invasion | 1.08 | (0.9) | 0.88 | (0.8) | |
Tumour inflammatory response | 0.39 | (0.06) | 0.40 | (0.09) | |
Tumour border configuration | 2.77 | ( 0.06 ) | 2.91 | (0.1) | |
Molecular parameters | MMR system | 1.54 | (0.6) | 0.97 | (1.0) |
CIMP | 0.58 | (0.2) | 0.60 | (0.3) | |
TS by mRNA | 1.15 | (0.7) | 1.31 | (0.5) | |
TS by IHC | 0.88 | (0.8) | 0.64 | (0.4) | |
TP53 | 0.62 | (0.2) | 0.37 | (0.08) | |
CTNNB1activation grades | 0.80 | (0.4) | 0.90 | (0.8) | |
 | BRAF c.1799 T > A | 2.57 | (0.04) | 3.68 | (<0.01) |